Optimer Pharmaceuticals to Present at June 2010 Investor Conferences

Jun 01, 2010, 08:00 ET from Optimer Pharmaceuticals, Inc.

SAN DIEGO, June 1 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9, 2010 at 9:30 a.m. Eastern Time at The Grand Hyatt in New York City.
  • 9th Annual Needham Healthcare Conference on Thursday, June 10, 2010 at 8:40 a.m. Eastern Time at the New York Palace Hotel in New York City.
  • ThinkEquity's Mid Year Check-Up on Healthcare on Wednesday, June 16, 2010 at 3:00 p.m. Eastern Time at The Princeton Club.

Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days after the presentations.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.

Contacts


Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736


Canale Communications, Inc.

Jason I. Spark, Senior Vice President

619-849-6005




SOURCE Optimer Pharmaceuticals, Inc.



RELATED LINKS

http://www.optimerpharma.com